Italia - italiană - AIFA (Agenzia Italiana del Farmaco)

novartis farma s.p.a. - carbamazepina - carbamazepina

Italia - italiană - AIFA (Agenzia Italiana del Farmaco)

alfasigma s.p.a. - tetracosactide - tetracosactide

Italia - italiană - AIFA (Agenzia Italiana del Farmaco)

eg s.p.a. - carbamazepina - carbamazepina

Italia - italiană - AIFA (Agenzia Italiana del Farmaco)

aurobindo pharma (italia) s.r.l. - carvedilolo - carvedilolo

Italia - italiană - AIFA (Agenzia Italiana del Farmaco)

ratiopharm gmbh - acido valproico - acido valproico

Italia - italiană - AIFA (Agenzia Italiana del Farmaco)

eg s.p.a. - acido valproico - acido valproico

Italia - italiană - AIFA (Agenzia Italiana del Farmaco)

noridem enterprises ltd - deferoxamina - deferoxamina

Italia - italiană - AIFA (Agenzia Italiana del Farmaco)

sanofi s.r.l. - vigabatrina - vigabatrina

Uniunea Europeană - italiană - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - neoplasie prostatiche - terapia endocrina - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Elveția - italiană - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - vigabatrinum - compresse rivestite con film - vigabatrinum 500 mg, excipiens pro compresso haze. - aed - synthetika